Epidemiology of symptomatic drug-induced long QT syndrome and torsade de pointes in Germany

Europace

Volumn 16, Issue 1, 2014, Pages 101-108

  Sarganas, Giselle ^a   Garbe, Edeltraut ^a,b,c   Klimpel, Andreas ^a   Hering, Rolf C ^a   Bronder, Elisabeth ^a   Haverkamp, Wilhelm ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b LEIBNIZ INSTITUTE FOR PREVENTION RESEARCH AND EPIDEMIOLOGY BIPS   (Germany)

^c UNIVERSITY OF BREMEN   (Germany)

Author keywords

Drug induced long QT syndrome; Germany; Incidence; Pharmacoepidemiology; QT QTc prolongation; Torsade de Pointes

Indexed keywords

AMIODARONE; CITALOPRAM; LEVOMETHADONE; MELPERONE; METOCLOPRAMIDE; POTASSIUM;

ADULT; AGED; ALCOHOLISM; ANOREXIA NERVOSA; ARTICLE; BRADYCARDIA; DEFIBRILLATOR; DIZZINESS; DRUG EXPOSURE; DRUG INDUCED DISEASE; DRUG SURVEILLANCE PROGRAM; DRUG WITHDRAWAL; FAINTNESS; FEMALE; GERMANY; HEART BUNDLE BRANCH BLOCK; HEART FAILURE; HEART VENTRICLE ARRHYTHMIA; HOSPITAL; HUMAN; HYPOKALEMIA; HYPOTHYROIDISM; INCIDENCE; INTERVIEW; ISCHEMIC HEART DISEASE; KIDNEY DISEASE; LONG QT SYNDROME; MAJOR CLINICAL STUDY; MALE; MEDICAL STAFF; MIDDLE AGED; PHYSICIAN; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; PROSPECTIVE STUDY; QT INTERVAL; QT PROLONGATION; RENAL DYSFUNCTION; RESUSCITATION; RISK FACTOR; SINUS NODE; TELEPHONE INTERVIEW; TORSADE DES POINTES; VERY ELDERLY; YOUNG ADULT;

DRUG-INDUCED LONG-QT SYNDROME; GERMANY; INCIDENCE; PHARMACOEPIDEMIOLOGY; QT/QTC PROLONGATION; TORSADE DE POINTES;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CAUSALITY; COMORBIDITY; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; GERMANY; HUMANS; INCIDENCE; LONG QT SYNDROME; MALE; MIDDLE AGED; RISK FACTORS; SEX DISTRIBUTION; SURVIVAL ANALYSIS; SURVIVAL RATE; TORSADES DE POINTES; YOUNG ADULT;

EID: 84889633152     PISSN: 10995129     EISSN: 15322092     Source Type: Journal    
DOI: 10.1093/europace/eut214     Document Type: Article

References (43)

1. Dessertenne F. [Ventricular tachycardia with 2 variable opposing foci]. Arch Mal Coeur Vaiss 1966;59:263-72.
2. Roden DM. Drug-induced prolongation of the QT interval. N Engl J Med 2004;350: 1013-22.
3. Shah RR. Can pharmacogenetics help rescue drugs withdrawn from the market? Pharmacogenomics 2006;7:889-908.
4. Laverty H, Benson C, Cartwright E, Cross M, Garland C, Hammond T et al. How can we improve our understanding of cardiovascular safety liabilities to develop safer medicines? Br J Pharmacol 2011;163:675-93.
5. Redfern WS, Carlsson L, Davis AS, Lynch WG, MacKenzie I, Palethorpe S et al. Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development. Cardiovasc Res 2003;58:32-45.
6. Curran ME, Splawski I, Timothy KW, Vincent GM, Green ED, Keating MT.Amolecu-lar basis for cardiac arrhythmia: HERG mutations cause long QT syndrome. Cell 1995;80:795-803.
7. The Uppsala Monitoring Centre. WHO Collaborating Centre forInternational Drug Mon-itoring. http://www.who-umc.org/DynPage.aspx.
8. Roden DM, Woosley RL, Primm RK. Incidence and clinical features of the quinidine-associated long QT syndrome: implications for patient care. Am Heart J 1986;111:1088-93.
9. Selzer A, Wray HW. Quinidine syncope. Paroxysmal ventricular fibrillation occurring during treatment of chronic atrial arrhythmias. Circulation 1964;30:17-26.
10. Kay GN, Plumb VJ, Arciniegas JG, Henthorn RW, Waldo AL. Torsadede pointes: the long-short initiating sequence and other clinical features: observationsin32 patients. J Am Coll Cardiol 1983;2:806-17.
11. Haverkamp W, Martinez-Rubio A, Hief C, Lammers A, Muhlenkamp S, Wichter T et al. Efficacy and safety of d, l-sotalol in patients with ventricular tachycardia and in survivors of cardiac arrest. J Am Coll Cardiol 1997;30:487-95.
12. Lehmann MH, Hardy S, Archibald D, quart B, MacNeil DJ. Sex difference in risk of torsade de pointes with d, l-sotalol. Circulation 1996;94:2535-41.
13. Hohnloser SH. Proarrhythmia with class III antiarrhythmic drugs: types, risks, and management. Am J Cardiol 1997;80:82G-9G.
14. Food and Drug Administration Cardiovascular and Renal Drugs Advisory Committee. Levitra Tablets (NDA 21-400) 2003. www.fda.gov/ohrms/dockets/ac/03/ slides/3956S1-03-Bayer.ppt (April, 2012)
15. Poluzzi E, Raschi E, Motola D, Moretti U, De Ponti F. Antimicrobials and the risk of torsadesdepointes: the contribution fromdataminingoftheUSFDA Adverse Event Reporting System. Drug Saf 2010;33:303-14.
16. Vieweg WV, Wood MA, Fernandez A, Beatty-Brooks M, Hasnain M, Pandurangi AK. Proarrhythmic risk with antipsychotic and antidepressant drugs: implications in the elderly. Drugs Aging 2009;26:997-1012.
17. Molokhia M, Pathak A, Lapeyre-Mestre M, Caturla L, Montastruc JL, McKeigue P. Case ascertainment and estimated incidence of drug-induced long-QT syndrome: study in Southwest France. Br J Clin Pharmacol 2008;66:386-95.
18. Garbe E, Andersohn F, Bronder E, Salama A, Klimpel A, Thomae M et al. Drug-induced immune thrombocytopaenia: results from the Berlin Case-Control Surveillance Study. Eur J Clin Pharmacol 2012;68:821-32.
19. Garbe E, Andersohn F, Bronder E, Klimpel A, Thomae M, Schrezenmeier H et al. Drug induced immune haemolytic anaemia in the Berlin Case-Control Surveillance Study. Br J Haematol 2011;154:644-53.
20. Sarganas G, Orzechowski HD, Klimpel A, Thomae M, Kauffmann W, Herbst H et al. Severe sustained cholestatic hepatitis following temozolomide in a patient with glio-blastoma multiforme: case study and review of data from the FDA adverse event reporting system. Neuro Oncol 2012;14:541-6.
21. Bazett HC. An analysis of the time-relations of electrocardiograms. Heart 1920;7: 353-70.
22. The Uppsala Monitoring Centre. The Use of the WHO-UMC System for Standardised Case Causality Assessment. http://www.who-umc.org/graphics/4409.pdf (2 January 2012)
23. WHO Collaborating Centre for Drug Statistics Methodology. The Anatomical Therapeutic Chemical Classification System with Defined Daily Doses (ATC/DDD). 2003. http://www.who.int/classifications/atcddd/en
24. Deutschland Regionalstatistik. Regionaldatenbank Deutschland. Düsseldorf2010; Available from: http://www.regionalstatistik.de/genesis/ online;jsessionid=9DE71A 1700AF2182E35C5CD292700FB8?Sequenz= tabelleErgebnis&selectionname= 173-21-4.
25. Viskin S, Rosovski U, Sands AJ, Chen E, Kistler PM, Kalman JM et al. Inaccurate electrocardiographic interpretation of long QT: the majority of physicians cannot recognize a long QT when they see one. Heart Rhythm 2005; 2:569-74.
26. Bai R, Yan GX. Accurate interpretation of the QT interval: a vital task that remains unaccomplished. Heart Rhythm 2005;2:575-7.
27. Haverkamp W, Monnig G, Schulze-Bahr E, Haverkamp F, Breithardt G. Physician-induced torsade de pointes-therapeutic implications. Cardiovasc Drugs Ther 2002;16:101-9.
28. Abi-Gerges N, Philp K, Pollard C, Wakefield I, Hammond TG, Valentin JP. Sex differences in ventricular repolarization: from cardiac electrophysiology to Torsades de Pointes. Fundam Clin Pharmacol 2004;18:139-51.
29. Makkar RR, Fromm BS, Steinman RT, Meissner MD, Lehmann MH. Femalegender as a riskfactor fortorsadesdepointes associated with cardiovascular drugs. JAMA 1993; 270:2590-7.
30. Kannankeril P, Roden DM, Darbar D. Drug-induced long QT syndrome. Pharmacol Rev 2010;62:760-81.
31. Roden DM. Cellular basis of drug-induced torsades de pointes. Br J Pharmacol 2008; 154:1502-7.
32. Pedersen HS, Elming H, Seibaek M, Burchardt H, Brendorp B, Torp-Pedersen C et al. Risk factors and predictors of torsade de pointes ventricular tachycardia in patients with left ventricular systolic dysfunction receiving Dofetilide. Am J Cardiol 2007;100: 876-80.
33. Shaffer D, Singer S, Korvick J, Honig P. Concomitant risk factors in reports of torsades de pointes associated with macrolide use: review of the United States Food and Drug Administration Adverse Event Reporting System. Clin Infect Dis 2002;35:197-200.
34. Bar KJ, Boettger MK, Koschke M, Boettger S, Groteluschen M, Voss A et al. Increased QT interval variability index in acute alcohol withdrawal. Drug Alcohol Depend 2007; 89:259-66.
35. Arizona CERT. Center for Education and Research on Therapeutics. www.azcert.org. (15 January 2011)
36. Poluzzi E, Raschi E, Moretti U, De Ponti F. Drug-induced torsades de pointes: data mining of the public version of the FDA Adverse Event Reporting System (AERS). Pharmacoepidemiol Drug Saf 2009;18:512-8.
37. Urge J, Sincl F, Prochazka V, Urbanek K. Terlipressin-induced ventricular arrhythmia. Scand J Gastroenterol 2008;43:1145-8.
38. Lehmann M, Bruns T, Herrmann A, Fritzenwanger M, Stallmach A. [54-year-old male with hepatic cirrhosis and therapy-associated torsadedepointestachycardia]. Internist (Berl) 2011;52:445-8, 50.
39. Hui WK, Mitchell LB, Kavanagh KM, Gillis AM, Wyse DG, Manyari DE et al. Melper-one: electrophysiologicand antiarrhythmicactivityin humans. J Cardiovasc Pharmacol 1990;15:144-9.
40. van Noord C, Straus SM, Sturkenboom MC, Hofman A, Aarnoudse AJ, Bagnardi V et al. Psychotropic drugs associated with corrected QT interval prolongation. J Clin Psychopharmacol 2009;29:9-15.
41. Alvarez PA, Pahissa J. QTalterations in psychopharmacology: proven candidates and suspects. Curr Drug Saf 2010;5:97-104.
42. Haugaa KH, Bos JM, Tarrell RF, Morlan BW, Caraballo PJ, Ackerman MJ. Institution-wide QT alert system identifies patients with a high risk of mortality. Mayo Clin Proc 2013;88:315-25
43. ICH E14. The Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs. Step 5 Questions and Answers. 2008. http://www.emea.europa.eu/docs/en-GB/document-library/Scientific- guideline/2009/09/WC500002878.pdf